Q-omics provides the consensus-scored SERPINA11 profile across patient tissues and cancer cell-line models. SERPINA11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SERPINA11 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, SERPINA11 RNA expression shows 10,619 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LIHC, and TGCT as cancer lineages where SERPINA11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINA11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINA11 survival associations across molecular data types. SERPINA11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINA11 RNA expression–survival associations across cancer types. High SERPINA11 expression shows unfavorable associations in UVM, KIRC and THCA, but favorable associations in SKCM, BRCA and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SERPINA11 RNA expression.
This table summarizes SERPINA11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SERPINA11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINA11 shows lower tumor expression in LIHC, CHOL and HNSC and higher tumor expression in BRCA, LUSC and THCA. The LIHC box plot shows higher SERPINA11 RNA expression in normal versus tumor tissue (log2 FC = −2.772, t-test p < 0.001).
This table shows molecular features associated with SERPINA11 in patient tissues and cancer cell lines. In patient samples, SERPINA11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINA11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
